EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever…
Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment with epcoritamab in combination with…
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of…
June 14, 2025 10:48 ET | Source: Celldex Therapeutics, Inc. 77% of patients (150 mg Q4W) treated with barzolvolimab who…
– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma – – Rademikibart reduced…
TAINAN, June 13, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the launch of its global Phase II clinical trial…
SINGAPORE, June 7, 2025 /PRNewswire/ -- On June 7, 2025, AB DAO announced that its native token $AB officially began trading…
June 06, 2025 16:07 ET | Source: Restem MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology…
June 06, 2025 16:05 ET | Source: PolyPid Ltd. PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD),…
DUBAI, UAE, June 6, 2025 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume, continues its advance in…